Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase II Study to Determine the Efficacy and Safety of Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A

NCT03700229 is registered in ClinicalTrials.gov with Peking Union Medical College Hospital as lead sponsor.

NCT NCT03700229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03700229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase II Study to Determine the Efficacy and Safety of Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A
Lead sponsor
Peking Union Medical College Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
October 10, 2018
Completion date
April 15, 2020
Enrollment
22 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acquired hemophilia a